/Quest%20Diagnostics%2C%20Inc_%20logo%20on%20building-by%20Tada%20Images%20via%20Shutterstock.jpg)
With a market cap of $19.3 billion, Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing and information services, offering routine, advanced, and specialty clinical testing to healthcare providers, patients, and organizations in the United States and internationally. It operates under brands such as Quest Diagnostics, AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, delivering services through an extensive network of laboratories and healthcare professionals.
The Secaucus, New Jersey-based company is slated to announce its fiscal Q4 2025 results soon. Ahead of the event, analysts expect DGX to report an adjusted EPS of $2.36, up 5.8% from $2.23 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in the past four quarterly reports.
